These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11019981)

  • 1. Prevalence of clotting factor deficiencies in a large population with von Willebrand disease.
    Nitu-Whalley IC; Hermans C; Lee CA
    Thromb Haemost; 2000 Sep; 84(3):514-5. PubMed ID: 11019981
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies?
    Lippi G; Franchini M; Poli G; Salvagno GL; Montagnana M; Guidi GC
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):361-4. PubMed ID: 17473578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent.
    Bauduer F; Ducout L
    J Thromb Haemost; 2004 Oct; 2(10):1724-6. PubMed ID: 15456482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined clotting factor deficiencies: experience at a single hemophilia treatment center.
    O'Brien SH; Ritchey AK; Ragni MV
    Haemophilia; 2007 Jan; 13(1):26-9. PubMed ID: 17212721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study.
    Koenig S; Gerstner T; Keller A; Teich M; Longin E; Dempfle CE
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):375-82. PubMed ID: 18600085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of bleeding severity in von Willebrand disease.
    Di Paola J
    Curr Hematol Rep; 2005 Sep; 4(5):345-9. PubMed ID: 16131434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of symptomatic von Willebrand disease in primary care practice.
    Bowman M; Hopman WM; Rapson D; Lillicrap D; James P
    J Thromb Haemost; 2010 Jan; 8(1):213-6. PubMed ID: 19874468
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet factor 3 availability test: an effective screening test for types 1 and 2 von Willebrand disease.
    Gupta PK; Ahmed R; Kannan M; Chatterjee T; Choudhry VP; Saxena R
    Ann Hematol; 2004 Jul; 83(7):489-90. PubMed ID: 15052373
    [No Abstract]   [Full Text] [Related]  

  • 10. Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
    Islam SI; Quadri MI
    East Mediterr Health J; 1999 Nov; 5(6):1188-95. PubMed ID: 11924110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of type 2b 'Malmö/New York' von Willebrand disease in Italy: the role of von Willebrand factor gene conversion.
    Baronciani L; Federici AB; Castaman G; Punzo M; Mannucci PM
    J Thromb Haemost; 2008 May; 6(5):887-90. PubMed ID: 18315546
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of acquired von Willebrand syndrome with AL amyloidosis.
    Kos CA; Ward JE; Malek K; Sanchorawala V; Wright DG; O'Hara C; Connors L; Skinner M; Seldin DC
    Am J Hematol; 2007 May; 82(5):363-7. PubMed ID: 17205535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined von Willebrand factor deficiency and factor XII deficiency.
    Bux-Gewehr I; Morgenschweis K; Zotz RB; Budde U; Scharf RE
    Thromb Haemost; 2000 Mar; 83(3):514-6. PubMed ID: 10744167
    [No Abstract]   [Full Text] [Related]  

  • 14. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact.
    Lukes AS; Kadir RA; Peyvandi F; Kouides PA
    Fertil Steril; 2005 Nov; 84(5):1338-44. PubMed ID: 16275227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting at the variable expressivity of von Willebrand disease.
    Levy G; Ginsburg D
    Thromb Haemost; 2001 Jul; 86(1):144-8. PubMed ID: 11487001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery.
    Franchini M; Zugni C; Veneri D; Gandini G; Lippi G; Manzato F; Brazzarola P
    Haematologica; 2004 Nov; 89(11):1341-6. PubMed ID: 15531456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of type 1 von Willebrand disease.
    Goodeve A
    Curr Opin Hematol; 2007 Sep; 14(5):444-9. PubMed ID: 17934350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unconventional diagnosis of Normandy-type von Willebrand's disease in a blood donor.
    Kashyap S; Nesbitt IM; Makris M
    Transfus Med; 2004 Apr; 14(2):181-4. PubMed ID: 15113383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3?
    Favaloro EJ
    J Thromb Haemost; 2008 Mar; 6(3):545-6. PubMed ID: 18088338
    [No Abstract]   [Full Text] [Related]  

  • 20. von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2.
    Veyradier A; Trossaert M; Lefrancois A; Fressinaud E; Meyer D
    J Thromb Haemost; 2007 Apr; 5(4):868-70. PubMed ID: 17408416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.